CIK 0001664710
- Non-accelerated filer
- Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 811173868
- Phone
- +1 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- 4 Derivatives Options or other derivatives
- 4 Open-market buy 10% owner bought 120,000 shares at $16.00 ($1,920,000)
- 4 Open-market buy Chief Executive Officer bought 20,000 shares at $16.00 ($320,000)
- 4 Open-market buy 10% owner bought 437,499 shares at $16.00 ($6,999,984)
- 4 Open-market buy Director bought 375,200 shares at $16.00 ($6,003,200)
- 4 Open-market buy Director bought 437,499 shares at $16.00 ($6,999,984)
- 4 Open-market buy Director bought 120,000 shares at $16.00 ($1,920,000)
- 4 Conversion Director acquired 915,725 shares (conversion)
- 4 Open-market buy Director bought 437,499 shares at $16.00 ($6,999,984)
- 4 Open-market buy Director bought 375,200 shares at $16.00 ($6,003,200)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 10 of 11 · 207 filings